|

Prognostic Significance of Fatty Liver Disease in Bariatric Patients

RECRUITINGN/ASponsored by Esbjerg Hospital - University Hospital of Southern Denmark
Actively Recruiting
PhaseN/A
SponsorEsbjerg Hospital - University Hospital of Southern Denmark
Started2018-08-15
Est. completion2035-06-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT03535142

Summary

Prospective non-randomized intervention case control study on patients with a BMI \> 35. The intervention group/cases (n=600) is comprised of bariatric patients who undergo bariatric surgery and the control group (n=600) of age, weight and comorbidity matched patients who choose not to undergo bariatric surgery. The overall aim is to examine prevalence of the spectrum of fatty liver disease (NAFLD) in these patients and the prognostic significance of NAFLD.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria case group:

* Age \> 18 years
* BMI \>35 kg/m2 and referred for bariatric surgery at Hospital of South West Jutland, Denmark
* Able to give written informed consent.

Inclusion criteria control group:

* Age \> 18 years
* BMI \>35 kg/m2 with no wish to undergo bariatric surgery.
* Able to give written informed consent.

Exclusion Criteria:

* Active viral hepatitis
* Not willing or able to consent
* Contraindications to liver biopsy

Conditions5

Liver DiseaseMetabolic EncephalopathyNon Alcoholic Fatty Liver DiseaseNon-Alcoholic SteatohepatitisObesity, Morbid

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.